Image-01 (Image 01)
Drospirenone And Ethinyl Estradiol
Product Images NDC 75834-116
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 75834-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image-02 (Image 02)
This text describes a likelihood chart of developing a VTE (Venous Thromboembolism), which is a type of blood clot, in non-pregnant women who use or do not use COC (combined oral contraceptives) and pregnant or postpartum women. The chart shows the number of women out of 10,000 women years who develop a blood clot in each group. The pregnancy data is based on actual duration and the assumption that the duration is nine months, with a rate of 7 to 27 per 10,000 WY.*
Image-03 (Image 03)
Drospirenone Ethinyl estadiol is a combination of two hormones used for birth control. Drospirenone is a type of progestin and ethinyl estradiol is a type of estrogen. It works by preventing ovulation, thickening cervical mucus to prevent sperm from reaching the egg, and thinning the lining of the uterus to prevent implantation.*
Image-04 (Image 04)
This text is not available as it contains misspelled words and unclear information.*
Image-05 (Image 05)
Image-06 (Image 06)
This text provides blood clot ranges for non-pregnant women, non-COC users, pregnant women, and postpartum women (up to 12 weeks only) based on the number of women who had a blood clot out of 10,000 Women Years (WY). However, the pregnancy data's rate is based on the actual duration (not assumed) of pregnancy in reference studies but also based on model assumption with a rate from 7 to 27 per 10,000 WY.*
Image-07 (Image 07)
Image-08 (Image 08)
The text appears to be a list of pharmaceutical-related information, including the name of a drug (Drospirenone and Ethinyl Estradiol Tablets), its dosage (3mg/0.02mg), and some technical details about the drug's composition and packaging. Without further context, it is difficult to provide a more detailed description.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
